Opening Asia for Russia

Thailand plans to register its own vaccine against COVID-19 by the end of the year

20.06.2022 ТАСС 79 просмотров

Currently, the drug ChulaCov19 is undergoing the third phase of clinical trials.

The Food and Drug Administration of Thailand plans to register the first coronavirus vaccine of its own production ChulaCov19 for emergency use by the end of this year. This was reported on Monday in the Department of Public Relations under the Government of the kingdom.

Currently, the drug ChulaCov19 is undergoing the third phase of human clinical trials. The vaccine is made from microscopic parts of the genetic material of the coronavirus without any use of infection. According to previously announced forecasts, the tests of the third phase should be completed by August of this year. In November last year, the authorities announced plans to approve this vaccination by mid-2022.

Meanwhile, the second drug HXP-GPO Vac, which uses the same production method as influenza vaccines, is currently undergoing the second phase of clinical trials. During the study, experts intend to find out whether it is able to protect against the omicron strain of coronavirus.

However, a nasal spray to protect against COVID-19 is expected to be released in the third quarter of 2022. At the moment, Thailand is developing a total of 20 different coronavirus vaccines.

In Thailand, which has a population of 69.6 million people, the first case of coronavirus infection was detected on January 13, 2020. On Monday, the Ministry of Health informed about 1.7 thousand infected and 18 dead per day. At the moment, the total number of infected has exceeded 4.5 million, more than 4.44 million people have been cured, 30.4 thousand patients have died. 53 million people have been fully vaccinated in the country.

Новости партнёров

Subscribe to Big Asia Newsletters

Subscribe and don't miss exclusive news